Ondansetron for the Treatment of Methamphetamine Dependence - 1
NCT ID: NCT00040053
Last Updated: 2017-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
154 participants
INTERVENTIONAL
2002-06-30
2004-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ondansetron for the Treatment of Cocaine Dependence - 1
NCT00033085
New Medication Treatment for Stimulant Dependence
NCT00689572
Studying Amphetamine Withdrawal in Humans
NCT01215929
PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)
NCT01377662
A Behavioral Trial for the Treatment of Methamphetamine Dependence. - 1
NCT00033124
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ondansetron
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Texas
OTHER
National Institute on Drug Abuse (NIDA)
NIH
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas Newton, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Institute on Drug Abuse (NIDA)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
South Bay Treatment Center
Chula Vista, California, United States
Matrix Institute on Addictions
Costa Mesa, California, United States
John A. Burns School of Medicine
Honolulu, Hawaii, United States
Powell Chemical Dependency Center
Des Moines, Iowa, United States
University of Missouri - Kansas City
Kansas City, Missouri, United States
University of Texas Health Science Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIDA-CTO-0011-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.